Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXY - Maxygen, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (39)	10/18/2000 7:11:06 PM
From: nigel bates	Respond to of 262

REDWOOD CITY, Calif., Oct. 18 /PRNewswire/ -- Maxygen (Nasdaq: MAXY - news) announced the issuance of U.S. Patent No. 6,132,970 further expanding its patent position for its proprietary MolecularBreeding(TM) directed molecular evolution technologies. The new patent broadly covers Maxygen's in vitro DNAShuffling(TM) recombination methods in a variety of formats, and contains multiple claims covering DNAShuffling(TM) recombination methods utilizing only a single cycle of screening. The patent also contains claims covering the application of Maxygen's DNAShuffling(TM) recombination methods to a variety of commercial targets including enzymes, antibodies, anti-cancer agents, viral proteins and vaccine vectors. ``This patent is a significant addition to our intellectual property portfolio,'' said Russell Howard, CEO of Maxygen. ``It is important because Maxygen can often produce significant improvements in desired commercial properties in the very first round of nucleic acid recombination and screening.'' With the issuance of this patent, Maxygen's intellectual property estate consists of 34 issued U.S. and international patents, including both patents owned by and licensed to Maxygen. Maxygen also has over 400 pending U.S. and international counterpart applications that it has filed on its own behalf or licensed from others....